Capital raising dependence
If the company cannot secure funding, development, manufacturing and sales activities may be limited or suspended.
- Scope
- working capital and expansion plans
- Materiality
- high
Nanologica
Nanologica is a Swedish life-science company that develops and manufactures porous silica materials used in preparative chromatography. Its products are designed for purification steps in pharmaceutical production, especially for peptide drugs such as insulin and GLP-1 therapies, and the company also provides application support and method development.
19
1.84
0.23
| % | |
|---|---|
| Silica-based purification media | 70% Porous silica materials used in preparative chromatography for pharmaceutical purification. |
| Ion-exchange chromatography media | 15% Complementary purification media for peptide drug separation and polishing steps. |
| Application support and method development | 10% Technical support to help customers evaluate, optimize and implement the media. |
| Customized chromatography solutions | 5% Tailored products and process support for specific customer purification workflows. |
Nanologica sells primarily to pharmaceutical companies and contract manufacturers that produce insulin, insulin...
- Pharmaceutical manufacturersprimary
Buy purification media for insulin, GLP-1 and other peptide-drug production because they need high-quality, scalable chromatography inputs.
- Contract development and manufacturing organizations (CDMOs)primary
Use the media in outsourced production workflows where purification performance, reliability and scale matter.
- Biosimilar producerssecondary
Evaluate the media for purification of biosimilar insulin and related peptide products as they scale manufacturing.
- Process development teamssecondary
Purchase small evaluation quantities and technical support to validate fit before production-scale adoption.
Nanologica sells through a sales organization that covers major markets, with dedicated coverage for India, China, the...
- •Sales coverage includes India, China, the United States and Europe
- •Revenue is largely USD-denominated, creating FX exposure
- •Costs include a meaningful GBP component from production and suppliers
- •Customer demand follows global peptide-drug manufacturing hubs
- •Geographic diversification matters for commercialization and scale
Nanologica’s strategy is to build a scalable business around high-performance silica media for peptide-drug...
01
Commercialize NLAB Saga®short-term
The core growth opportunity depends on converting customer evaluations into production-scale adoption.
02
Broaden the chromatography portfoliomedium-term
Complementary products increase the addressable market and improve customer retention.
03
Scale production and technical capabilitymedium-term
Reliable supply and consistent product quality are essential for industrial pharmaceutical customers.
Nanologica faces financing, commercialization and execution risks typical of an early commercial-stage life-science...
Commercialization risk
Revenue depends on converting technical evaluations into repeat production orders, which can take 3-18 months.
- Scope
- NLAB Saga® and related products
- Materiality
- high
Product performance and customer testing risk
Different customers use different methods and conditions, so products may perform differently in trials.
- Scope
- customer qualification and adoption
- Materiality
- high
Manufacturing and supply-chain risk
Production relies on contract manufacturers, raw materials and specialized equipment, creating delay and quality risk.
- Scope
- silica media production
- Materiality
- high
Foreign exchange risk
A large share of revenue is in USD while costs are partly in GBP, so exchange-rate moves affect results.
- Scope
- SEK/USD and SEK/GBP
- Materiality
- medium
Key-person dependence
The company is small and depends heavily on specialized management and technical staff.
- Scope
- R&D, production and sales execution
- Materiality
- medium
Inventory valuation and write-downs
affects cost of sales, inventory and operating profit
Manufacturing cost allocation
affects inventory carrying values and gross margin
IFRS 16
Lease accounting under IFRS 16
affects balance sheet and operating expense presentation
Loss carryforwards
affects deferred tax assets and equity
: 11/08/2026